Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance
Journal of Medicinal Chemistry · 13.03.2025 · 68 (5) · 5597-5615
DOI: 10.1021/acs.jmedchem.4c02840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.02.2025. Verfasst von Meng Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: National & Local Joint Engineering Research Center for Mineral Salt Deep Utilization, Institute of Green Chemistry and Process Enhancement Technology…. Hauptthemen laut MEDLINE: Cisplatin, Antineoplastic Agents, Prodrugs, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Huaiyin Institute of Technology, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Acquired resistance in cancer remains a significant challenge in oncology, posing obstacles to the efficacy of diverse therapeutic approaches. The nuclear factor-kappa B (NF-κB) signaling pathway plays an important role in the development of drug resistance in tumor cells. Herein, we employed NF-κB inhibitors and cisplatin to synthesize multitarget Pt(IV) antitumor prodrugs. Among them, the antiproliferation activity of complex 8 demonstrated a remarkable 146.92-time increase compared to cisplatin against A549/CDDP cells. Moreover, complex 8 could effectively induce DNA damage, promote ROS generation, induce autophagy, trigger the mitochondrial apoptosis pathway, and suppress cell proliferation through the NF-κB signaling pathway. Furthermore, complex 8 effectively downregulated the levels of VEGF and HIF-1α and exerted antiproliferative activity through the PI3K/AKT and STAT-3 pathway in A549/CDDP cells. Interestingly, complex 8 showed a superior in vivo antitumor activity than cisplatin, 5a, or their combination, suggesting its potential as a promising candidate for further drug development in lung cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National & Local Joint Engineering Research Center for Mineral Salt Deep Utilization, Institute of Green Chemistry and Process Enhancement Technology, Huaiyin Institute of Technology, Huai'an 223003, China.
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Inno…
- Guangxi Key Laboratory of Drug Discovery and Optimization, School of Pharmacy, Guilin Medical University, Guilin 541199, China.
ORCID-Profile: Hengshan Wang
Förderung
- Huaiyin Institute of Technology
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Guangxi Key Laboratory of Drug Discovery and Optimization
- National & Local Joint Engineering Research Center for Mineral Salt Deep Utilization
Zitieren
APA
Wang, M., Li, G., Xu, N., Wang, L., Cai, J., Huang, R., Yang, Y., Chen, G., Liu, Z., Zhang, Y., Wang, H., & Huang, X. (2025). Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance. Journal of Medicinal Chemistry, 68(5), 5597-5615. https://doi.org/10.1021/acs.jmedchem.4c02840
Vancouver
Wang M, Li G, Xu N, Wang L, Cai J, Huang R, et al. Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance. Journal of Medicinal Chemistry. 2025;68(5):5597-5615. doi:10.1021/acs.jmedchem.4c02840
BibTeX
@article{Wang2025,
author = {Wang, Meng and Li, Guimei and Xu, Nan and Wang, Lang and Cai, Jinyuan and Huang, Rizhen and Yang, Yong and Chen, Guiping and Liu, Zhikun and Zhang, Ye and Wang, Hengshan and Huang, Xiaochao},
title = {Discovery of a Novel EF24 Analogue-Conjugated Pt(IV) Complex as Multi-Target Pt(IV) Prodrugs Aims to Enhance Anticancer Activity and Overcome Cisplatin Resistance},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {5},
pages = {5597--5615},
doi = {10.1021/acs.jmedchem.4c02840}
}
EUVIMED